DONALD PARSONS to Glioma
This is a "connection" page, showing publications DONALD PARSONS has written about Glioma.
Connection Strength
1.047
-
Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial. J Clin Oncol. 2022 07 10; 40(20):2235-2245.
Score: 0.526
-
Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions. Clin Cancer Res. 2025 Feb 03; 31(3):561-572.
Score: 0.160
-
Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations. Neuro Oncol. 2019 08 05; 21(8):968-980.
Score: 0.109
-
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med. 2015 Jun 25; 372(26):2481-98.
Score: 0.082
-
Germline mutations in shelterin complex genes are associated with familial glioma. J Natl Cancer Inst. 2015 Jan; 107(1):384.
Score: 0.079
-
IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009 Feb 19; 360(8):765-73.
Score: 0.053
-
Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors. J Clin Oncol. 2024 Aug 10; 42(23):2769-2779.
Score: 0.038